Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Chemoradiotherapy in HNSCC
NCT02764593Phase 1Completed
- Sponsor
- RTOG Foundation
- Start
- Jun 2016
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by RTOG Foundation. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02764593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764593.